TABLE 3.
Comparison of patient characteristics according to katG-463 and gyrA-95 genotype of corresponding isolate
| Characteristic | Group 1 (n = 61) | Group 2 (n = 270) | Group 3 (n = 84) | P value |
|---|---|---|---|---|
| Mean (SD) age (yr) | 49.8 (16.8) | 42.6 (16.0) | 45.2 (15.9) | <0.05ab |
| No. (%) of subjects | ||||
| Female | 10 (16.4) | 61 (22.6) | 13 (15.5) | 0.26 |
| Male | 51 (83.6) | 209 (77.4) | 71 (84.5) | |
| Asian | 9 (14.8) | 12 (4.4) | 1 (1.2) | <0.05ac |
| Black | 20 (32.8) | 108 (40.0) | 35 (41.7) | 0.51 |
| Hispanic | 4 (6.6) | 22 (8.1) | 7 (8.3) | 0.91 |
| White | 28 (45.9) | 126 (46.7) | 40 (47.6) | 0.98 |
| Other | 2 (0.7) | 1 (1.2) | ||
| HIV positive | 30 (49.2) | 127 (47.0) | 31 (36.9) | 0.21 |
| HIV negatived | 31 (50.8) | 143 (53.0) | 53 (63.1) | |
| Ever smear positive | 38 (62.3) | 146 (54.1) | 43 (51.2) | 0.39 |
| Always smear negative | 7 (11.5) | 46 (17.0) | 15 (17.9) | 0.52 |
| Fewer than three sputum smears | 16 (26.2) | 78 (28.9) | 26 (31.0) | 0.83 |
| Infectivity | ||||
| Mean % (SD) | 29.1 (35.0) | 30.7 (36.9) | 35.6 (38.2) | 0.53 |
| No. (%) of patients highe | 20 (37.0) | 99 (40.1) | 34 (44.7) | 0.65 |
| No. (%) of patients lowf | 34 (63.0) | 148 (59.9) | 42 (55.3) | |
| Pathogenicity | ||||
| Mean % (SD) | 5.4 (19.7) | 5.5 (18.2) | 7.1 (21.8) | 0.80 |
| No. (%) of patients highg | 6 (10.7) | 29 (11.5) | 10 (12.8) | 0.92 |
| No. (%) of patients lowh | 50 (89.3) | 223 (88.5) | 68 (87.2) | |
| Mean no. of contacts | ||||
| Named | 11.9 (27.0) | 8.8 (20.1) | 11.9 (36.2) | 0.50 |
| Screened | 11.2 (26.8) | 8.0 (19.9) | 11.3 (36.2) | 0.50 |
| Followed up | 11.1 (26.5) | 7.5 (18.3) | 10.9 (36.0) | 0.37 |
a
Denotes a statistically significant difference at an α-level of 0.05.
b
For group 1 versus group 2, P = 0.002.
c
For group 1 versus group 2, P = 0.007; for group 1 versus group 3, P = 0.004.
d
Includes subjects whose HIV status is unknown.
e
Patients demonstrating high (>30.0%) infectivity.
f
Patients demonstrating low (≤30.0%) infectivity.
g
Patients demonstrating high (>10.0%) pathogenicity.
h
Patients demonstrating low (≤10.0%) pathogenicity.